Kisspeptin-10

What it is

Kisspeptin-10 is a short 10-amino-acid fragment of kisspeptin, a naturally occurring peptide that the body uses to help control the reproductive hormone axis S5. It acts high up in that axis by stimulating the release of gonadotropin-releasing hormone (GnRH), which in turn drives the pituitary to release the reproductive hormones LH and FSH S5. In human studies, kisspeptin-10 is a potent stimulator of LH and can increase the pulse frequency of its release in men S2. Because it works upstream of the body's own hormone machinery rather than replacing a hormone directly, researchers describe it as a tool for probing and potentially restarting endogenous reproductive signalling S5.

Marketed as

In legitimate settings kisspeptin-10 appears only as an investigational research compound and a laboratory reagent, not as a consumer product S4. Outside those settings it also circulates on the gray market, where it is promoted informally around themes of fertility, libido, and hormone support S5. None of these gray-market presentations reflect an approved medicine, and this page does not endorse or describe any such use.

Regulatory status (US)

As of 2026, kisspeptin-10 is not FDA-approved for any indication, and there is no NDA or ANDA for any kisspeptin product in the United States S4. Human work with the peptide and its analogues takes place under research protocols rather than as an approved therapy S1. Material offered outside those protocols is unapproved.

Around the world

The most prominent human research program has been run in the United Kingdom by teams at Imperial College London and Imperial College Healthcare NHS Trust, led by Professor Waljit Dhillo and Dr Ali Abbara S1. That group has studied kisspeptin and a longer-acting analogue (MVT-602) in fertility contexts including polycystic ovary syndrome and hypothalamic amenorrhea S1. It has also examined kisspeptin as a physiological trigger for egg maturation as a way to make IVF safer for some patients S6. This remains investigational research rather than approved care in any jurisdiction S1.

Evidence

The human evidence base is real but early. Controlled studies show that kisspeptin-10 stimulates LH release and increases LH pulse frequency in men S2, and that its effects on reproductive hormone release differ between the sexes S5. A randomized clinical trial reported that kisspeptin administration modulated sexual brain processing and penile responses in men with hypoactive sexual desire disorder S3, which the investigators frame as a mechanism-level finding rather than an approved treatment. In fertility work, an analogue produced roughly four times longer hormonal stimulation than natural kisspeptin in a small early-stage study S1. Investigators consistently caution that more research is needed to fully determine its effects on more patients S1.

Anti-doping

Because kisspeptin-10 acts on the hormone axis, it draws attention from anti-doping bodies. Kisspeptin is not currently named as a specific substance on the WADA Prohibited List S4; however, WADA's peptide-hormone category is broadly defined, and athletes cannot assume that a compound stimulating endogenous hormone production is automatically permitted S4. Doping-control laboratories have begun developing analytical methods for kisspeptin and its analogues, which signals ongoing interest even where no explicit ban exists S5.

Safety

Most documented human exposure to kisspeptin-10 comes from supervised research, where short-term single-dose administration has generally been reported without notable side effects in small samples S1. That is not the same as an established safety profile: the effects of unsupervised, repeated, or gray-market use have not been characterized S1. Anyone encountering kisspeptin outside a formal trial should treat it as an unapproved, investigational substance and prioritize verifying that any provider or protocol is legitimate and clinician-supervised S4.

What's changing

Kisspeptin research continues to move forward, with academic groups extending work into reproductive disorders and continued interest in analogues that last longer in the body than the native peptide S1. Whether any kisspeptin compound reaches a defined, approved indication depends on later-phase trials that have not yet concluded S1. On the anti-doping side, the growth of detection-method research suggests the compound could receive more explicit regulatory attention over time, so athletes should consult their governing body rather than relying on current list wording S4.